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Abstract 
In August 2019 an unexplained, exponential rise in severe respiratory illnesses in previously 
healthy young adults, swept across America catching the attention of medical providers. Hospital 
admissions for lung injury increased 10-fold over two months’ time leaving practitioners 
scrambling for answers. All affected patients were found to have used e-cigarettes prior to 
symptoms and endorsed using nicotine and marijuana vape pens. The medical community 
quickly began to search for the cause of these vaping associated lung injuries. Understanding the 
mechanism of injury is important in order to assist in educating the public about the risks 
associated with e-cigarettes. The aim of this paper is to present the research, or lack thereof, 
surrounding the risks of electronic cigarettes and their association with severe lung injury. A 
thorough literature review was performed eliciting 12 appropriate studies. A conclusive causative 
agent for EVALI has not been identified but several possible culprits are Vitamin E Acetate, 
propylene glycol or glycerol and metal nanoparticles. Recommendations for future research, 
provider and patient education and policy change are provided. 
 
Keywords: vaping, e-cigarettes, adolescents, cannabis, cannabidiol, lung injury, lung 
disease 
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A Search for the Cause of Vaping Associated Lung Injury in Adolescents 
 In the late summer months of 2019, the Centers for Disease Control were inundated with 
reports of severe lung disease in previously healthy adolescents and youth. Through chart review 
and interview, the common denominator between all ill patients was the use of e-cigarettes. E-
cigarettes, or vapes, are part of a $2.5 billion-dollar industry (Truth Initiative, 2019). Like 
cigarettes of the past, there is rising concern that e-cigarette companies are targeted adolescents 
through marketing strategies and by adding flavors to create nicotine addicts at a young age.  
In addition to this concern, increasing number of adolescents are vaping other substances, 
particularly cannabis products including tetrahydrocannabinol (THC) and cannabidiol (CBD). 
The combination of e cigarettes and marijuana was ‘all but inevitable,’ (Poklis, 2019, p. e25), but 
the repercussion of this combination was not anticipated. As legalization of marijuana continues 
to gain traction, it is expected that there will be an increase in the amount of marijuana that is 
vaped. With anticipation of this, providers should be knowledgeable about the causes of vaping 
associated lung injury and well versed in the risks associated with vaping. This literature review 
will attempt to identify the best evidence associated with vaping associated lung injury in 
adolescents and inform the professional recommendations. 
Background 
E-cigarettes were first introduced to the market in 2007. A major concern around 
electronic cigarettes has been inappropriate marketing. For years, there has been concern 
throughout the medical community regarding the lack of research to support claims that e-
cigarettes are a safer alternative to traditional smoking. While still addictive, these devices have 
been marketed as healthier alternatives since they decrease the amount of inhaled toxic smoke 
compared to combustible cigarettes (Budney, et al., 2015).  This claimed benefit of vaping is 
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proposed to be due to the inhalation of aerosol liquids with fewer chemicals than the thousands 
found in cigarette smoke (Palazzolo, 2013). Unfortunately, these claims may be false due to the 
higher numbers of chemicals in vaping solution than originally thought, and lack of longitudinal 
studies to address the effects of long-term vaping (Budney, et al., 2015).  Moreover, even though 
ingredients used in e-cigarettes have been deemed safe by the Food and Drug Administration 
(FDA) for consumption but many of them have not been approved for inhalation (Truth 
Initiative, 2019). 
Combustible cigarettes are the leading cause of preventable deaths in the United States so 
finding products to aid in smoking cessation is imperative (Truth Initiative, 2019). E-cigarette 
companies took advantage of this notion and initially promoted themselves as smoking 
alternatives. In response to this, the FDA sent warning letters since these claims were not based 
in fact or supported by research. In fact, the FDA recommended that e-cigarettes be labeled as 
dangerous nicotine delivery devices that should be regulated by the Federal Food Drug and 
Cosmetic Act (Palazzolo, 2013). After numerous rounds of legal battles, the US Court of 
Appeals stated that e-cigarettes must be marketed as a smokeless tobacco product (even though 
they contain trace amounts of tobacco and smoke) and cannot be marketed as smoking cessation 
aides or a healthier option until research could support these claims (Palazzolo, 2013).    
These devices quickly evolved to include nicotine, THC, CBD, and flavorings to make 
them more appealing to consumers. Various types of e-cigarettes are available with the newest 
generation of vape pens being created by JUUL in 2015. These pens are sleek, reusable, and 
easily rechargeable. JUUL quickly became the number one e-cigarette company supplying over 
three-quarters of the market (Truth Initiative, 2019).   
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The term vaping refers to the inhalation of a combination of propylene glycol, active 
ingredients (i.e. nicotine or THC), water and flavorings that have been vaporized (Budney, 
Sargent & Lee, 2015). Through this process, the desired liquid, as well as biproducts from the 
device, are inhaled. With legislation pushing for increased legalization of marijuana, vaping 
THC will continue to rise (Budney, Sargent & Lee, 2015).  Healthcare providers must be 
informed about vaping and the associated health consequences as use continues to climb with 
over nine million adults using e-cigarettes with nicotine or other substances (Truth Initiative, 
2019). 
In the summer of 2019, healthcare providers noted an abrupt increase in severe 
respiratory symptoms in adolescents and young adults. These individuals (average age of 24 
years) had an acute onset of respiratory distress leading to lipoid pneumonia, acute respiratory 
distress syndrome and even death (Moritz, et al., 2019). Through careful review, pulmonologists 
and cricial care physicians identified the common denominator between these patients was 
vaping. Therefore, these individuals were diagnosed with electronic-cigarette or vaping 
associated lung injury (EVALI).   This outbreak lead to 2,807 hospitalized cases and 68 deaths 
among all 50 states (Truth Initiative, 2019).  
Vaping has been around since 2009 with minimal serious side effects. So, what caused 
this significant uptick in cases requiring hospitalization and killing otherwise healthy young 
people? Throughout the outbreak hypotheses poured in regarding possible contaminations or 
toxins that could be the culprit. A theory that had gained support was the idea that vaping 
marijuana along with the associated additives was the cause of these symptoms. As a result, the 
Centers for Disease Control and Prevention (CDC) recommended cessation of vaping marijuana 
and to vape other substances with caution until a causative agent could be identified (Siegel, et 
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al., 2019). Therefore, the clinical question guiding this paper is as follows: Are adolescents who 
vape cannabis (or cannabinoids) at increased risk for lung disease or injury compared with 
those who do not vape cannabis? 
Methods 
 Beginning on October 10, 2019, an extensive literary search began utilizing various 
databases selected for their content and accessibility. The search concluded on November 12, 
2019. The databases utilized included CINAHL, MEDLINE (PubMed), Cochrane, Academic 
Search Premier, and Nursing and Allied Health Database. Searches were limited by the 
following criteria: full-text, peer reviewed, and published between 2015 and 2019 (see Table 1of 
the Appendix for general subjects covered by each selected database). Search terms were 
variations of the original clinical question and included “vaping,” e-cigarettes,” “vaping 
cannabis,” “cannabidiol,” “lung injury,” “lung disease,” “adolescents,” and “teens.” All searches 
that yielded less than 100 results were reviewed for relevance and applicability to the clinical 
question. Refer to Table 2 in the Appendix for search results broken down by search terms and 
databases. After review of all search combinations and databases, 72 articles were included for 
further review. Articles were chosen after reviewing abstracts for applicability to the clinical 
question.  
 Articles that pertained to the outbreak of lung disease in late 2019 were included. Articles 
that discussed the pathophysiology of lung injury, possible causative agents of lung injury and 
interim guidelines were included. Articles discussing various types of vaporized marijuana 
products including THC and CBD, and possible contaminants were included. Articles that 
compared vaping to cigarette use were excluded. Articles which compared vaporized nicotine to 
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non-nicotine containing e-cigarettes were excluded. See Table 3 in Appendix for a detailed 
summary of the articles included or excluded along with the rationale.  
 The 12 studies that met inclusion criteria were reread and analyzed to identify key 
findings that will affect practice and level of evidence. The levels of evidence (Melnyk and 
Fineout-Overholt, 2015) ranged from Level II-Level VII (1 Level II, 2 Level III, 2 Level IV, 2 
Level V, 1 Level VI, and 4 Level VII). Among the varying levels of evidence there was a 
combination of randomized control trial reviews, single cohort/case studies, laboratory studies, 
and expert opinions. The limited number of high-quality research articles was mentioned by 
authors of several articles further identifying a need for increased research into EVALI. 
Description of studies with associated findings and level of evidence can be found in Table 4 of 
the Appendix. 
Literature Review 
 With their introduction to the market in 2007, e-cigarettes had a level of speculation from 
the beginning. Promoted as a safer alternative to combustible cigarettes, critics were quick to 
notice a lack of research to support these claims. Electronic cigarette companies proposed that 
their products were healthier since consumers were inhaling lower number of chemicals when 
compared to cigarette smoke (Budney, et al., 2015). While this is a potential benefit as many of 
the ingredients in vaping solution are deemed safe for consumption by the FDA, there are no 
longitudinal studies on the long-term effects of inhaling these chemicals has on lung tissue and 
overall health (Budney, et al., 2015). Budney, Sargent and Lee (2015) referred to electronic 
cigarettes as a “double-edged sword” where practitioners must outweigh the potential, unknown 
risk with the benefit of working towards smoking cessation.  
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 Palazzolo and colleagues (2013) had similar concerns with the lack of scientific research 
to support e-cigarette company’s health claims. Through a literature review, the researchers 
found that vaping was “as effective” as other FDA approved nicotine replacement therapies, such 
as registered Nicotrol inhalers (Palazzolo, et al., 2013). These claims mean that companies 
cannot market electronic cigarettes as healthier options. In 2010, the US Court of Appeals 
deemed these products must be labeled as dangerous nicotine delivery device and marketing 
must not be directed at minors (Palazzolo, et al., 2013).  
Electronic cigarette designs have changed immensely since their consumption and now 
are discrete and difficult to identify. This feature has led to the increasing use of electronic 
cigarettes in non-smoking areas and threatening anti-smoking initiatives (Truth Initiative, 2020). 
Additionally, there is fear that electronic cigarettes are geared towards a new generation of 
potential nicotine addicts (Palazzolo, et al., 2015). This again presents electronic cigarettes as a 
double-edged sword: will they decrease the amount of combustible cigarettes consumed while 
increasing rates of new and younger electronic cigarette users (Palazzolo, et al., 2015)?  
 The difficult situation for providers is the risk management in patients. Combustible 
cigarettes are the leading cause of preventable death in the United States, so action is needed to 
combat this epidemic (Palazzolo, et al., 2015). Without longitudinal studies, providers cannot 
accurately state that there will not be long-term health effects on these young patients (Budney, 
Sargent & Lee, 2015). Researchers feared that the lack of research would lead to deleterious 
outcomes for consumers. Unfortunately, this fear came true in the summer of 2019.  
Providers in numerous states began reporting numerous cases of severe, respiratory 
symptoms in young patients. Patients initially presented with vague symptoms of low-grade 
fevers, tachypnea, dyspnea, hypoxia with oxygen saturations less than 90% of room air, nausea, 
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vomiting and abdominal discomfort (Davidson, et al., 2019). Clinicians were confounded by 
these debilitating symptoms that lasted for several weeks in young adults. Searching for a cause, 
data was compiled at the CDC and the Lung Injury Response Clinical Working Group was 
created (Siegel, et al., 2019). This group consisted of nine practitioners leading the field in 
pulmonary medicine (pediatric and adults), and critical care across the country (Siegel, et al., 
2019). It was found that 86% of the 1,604 cases presented at that time had vaped THC (Moritz, 
et al., 2019). Therefore, these individuals were diagnosed with EVALI (Moritz, et al., 2019).  
As cases continued to role in and the death toll rose, the CDC recommended that 
individuals avoid all THC containing vaping products and to use caution with other vaping 
products as the causative agent remained unknown (Moritz, 2019). Recommendations for 
clinicians included asking a detailed social history surrounding vaping of any patient who 
presented with respiratory symptoms. These questions would include substance vaped (nicotine, 
cannabis, other substance or unknown), where this substance was obtained, frequency and 
quantity of vaping (Siegel, et al., 2019). If EVALI was suspected, chest x-ray was the first 
indicated test. Laboratory tests included a complete blood count (CBC), erythrocyte 
sedimentation rate (ESR), respiratory viral panel, and urine toxin screen (Siegel, et al., 2019). 
Chest radiograph of patients with EVALI would show bibasilar infiltrates with ground glass 
opacities (Viswam, et al., 2019). CBC may be normal or have an increased white blood cell 
count without eosinophilia (Viswam, et al., 2019).  
EVALI is a diagnosis of exclusion ruling out other etiologies related to infectious (viral 
or bacterial) allergic, or toxic sources. The elimination of differential diagnoses helps to raise 
suspicion for EVALI. Siegel et al., (2019) stated patients with suspected EVALI should be 
admitted to the hospital if oxygen saturations are less than 95% on room air, the patient has 
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symptoms of respiratory distress (tachypnea, increased work of breathing) or has comorbidities 
of asthma, tuberculosis, cystic fibrosis or chronic obstructive pulmonary disease that will 
decrease their respiratory reserve (Siegel, et al., 2019). Patients that do not meet these criteria but 
have suspected EVALI should be treated empirically for community acquired pneumonia with 
ceftriaxone and azithromycin and followed up within 24-48 hours (Davidson, et al., 2019; Siegel, 
et al., 2019).  
Patients with EVALI who were admitted to the hospital required supplemental oxygen 
and several required mechanical ventilation due to the severe lung injury (Dicpinigaitis, et al., 
2019). Computed tomography scan of the chest confirmed chest radiograph findings of diffuse 
basilar-predominant infiltrates with ground-glass opacities but also showed tree-in bud infiltrates 
(Davidson, et al., 2019). Tree-in-bud infiltrates indicate a degree of airway obstruction and this 
obstruction was confirmed on spirometry testing showing a restrictive ventilatory defect 
(Viswam, et al., 2018). Patients were treated with methylprednisone for the obstruction and 
symptoms improved (Davidson, et al., 2019). Several patients had bronchoscopy completed with 
bronioalveolar lavage that was negative for alveolar hemorrhage but showed lipid-laden 
macrophages (Dicpinigaitis, et al., 2019). One patient had video-assisted thoracoscopic surgical 
lung biopsy (VATS biopsy) showing lipid filled macrophages, high levels of cholesterol deposits 
and inflammation (Viswam, et al., 2018).  
Therefore, it was concluded that EVALI symptoms were a result of exogenous lipoid 
pneumonia (Davidson, et al., 2019). With an identified disease, clinicians still needed to find the 
cause of the lipoid pneumonia. Why was there a sudden influx of cases when electronic 
cigarettes had been available for over ten years? The initial thought was there must be a 
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connection between marijuana and EVALI since almost 90% of EVALI patients had vaped 
marijuana (Moritz, et al., 2019).  
Currently, recreational marijuana is legal in 11 states and medicinal marijuana is legal in 
47 states (McNamara, 2020). As rates of legalization increase, so do rates of marijuana being 
vaped and the age of users is decreasing (Knopf, 2018). No person under the age of 21 should 
have access to marijuana outside of medical purposes. Research has shown that cannabis use in 
adolescence leads to decreased brain development, lower educational achievement and inferior 
psychosocial functioning (Knopf, 2018). Adolescents and children that live in areas with high 
rates of marijuana dispensaries are twice as likely to vape marijuana and have a younger age of 
onset than children from other areas (Knopf, 2018).  
In addition to the risks associated with vaping marijuana, there are also risks of vaping 
unregulated products. In states where recreational marijuana is not legal, companies have started 
to promote CBD as a safer option. CBD and THC are the two main components of marijuana 
(Poklis, et al., 2018). THC gives users the ‘high’ sensation and is viewed as more controversial 
than CBD. CBD has been promoted as a sleep aid, anxiolytic and antidepressant (Poklis, et al., 
2018). CBD products are permitted to have up to 0.3% THC. Unfortunately, there is no 
manufacturing standards to ensure the safety or quality of CBD (Poklis, et al., 2018).  
Nine commercially available CBD vaping oils were reviewed and two serious 
cannabimimetics were identified. The first was 5F-ADB which is a Drug Enforcement Agency 
(DEA) Schedule 1 drug due to side effects of agitation, psychosis, tachycardia and death. The 
other substance, dextromethorphan, is found antitussives and has numerous drug-to-drug 
interactions leading to contraindications. Additionally, there is limited information about the 
effects of dextromethorphan when inhaled. Dextromethorphan leads to roughly 30 poisonings a 
 12 
year for adolescents aged 13-18 (Poklis, et al., 2018). This is an extremely dangerous finding as 
CBD has been marketed as safe and there was no listing of potential contaminants or side effects 
that could happen from these impurities.    
 As the number of EVALI cases rose significantly in the summer/fall of 2019, clinicians 
scrambled to find a cause. Due to the lack of regulation, there were numerous possible causative 
agents. The first potential culprit that was investigated as the hygroscopic substances used in 
vaping liquid. Propylene glycol and glycerol are commonly used as humectants in conjunction 
with flavoring and nicotine, THC or other substances (Chaumont, et al., 2019). Propylene glycol 
is the main ingredient in many e-cigarette cartridges and can make up 90% of the content 
(Palazzo, 2013). These substances are labeled “generally safe” when ingested but research is 
lacking on how these substances affect the body when inhaled. This is an important question 
since the lung tissue is a moist environment and hygroscopic substances absorb fluids. 
Researchers hypothesized that propylene glycol and glycerol would lead to dehydration of lung 
tissues, and alterations in mucocilliary clearing system causing airway obstruction (Chaumont, et 
al., 2019). These substances are unable to cross biological membranes and foreign substances 
can trigger proinflammatory cytokines further irritating the airways and leading to airway 
constriction (Chaumont, et al., 2019). 
 Unfortunately, nicotine has shown similar inflammatory responses and damages in lungs 
leading to chronic obstructive pulmonary disease and cancers. With this new method of nicotine 
(or other substance) delivery, it is important to identify other potentially harmful ingredients. The 
researchers’ goal was to identify if propylene glycol and glycerol had similar or worse effects on 
lung tissue as nicotine (Chaumont, et al., 2019).  
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 Twenty-five young men (median age 23 years) were recruited to assess the impact of 
propylene glycol and glycerol on lung function (Chaumont, et al., 2019). The individuals were 
randomly assigned electronic cigarettes with only propylene glycol and glycerol and electronic 
cigarettes with these materials and nicotine (Chaumont, et al., 2019). Prior to vaping, 30 minutes 
after and 150 minutes after, pulmonary function tests (PFTs) as well as blood and urine samples 
were obtained (Chaumont, et al., 2019).  Pulmonary function testing as well as arterial tension 
testing showed airway constriction and decreased oxygen levels at 30- and 150-minute intervals 
for both groups (Chaumont, et al., 2019).  This shows that nicotine is not the causative agent of 
respiratory issues in individuals who smoke but in fact the propylene glycol and glycerol were 
the cause (Chaumont, et al., 2019).  It is proposed that these substances were deposited in the 
epithelium of large airways as well as embedding in the terminal portions of the bronchioles and 
alveoli (Chaumont, et al., 2019). 
 Another causative agent that was investigated was metal nanoparticles that were released 
from the coil heating agent in vape pens. Since there is no combustion in electronic cigarettes or 
vape pens, a metal coil is used as the heating device (Lerner, et al., 2016). When the pen is 
turned on, the coil heats up, causing the liquid vape solution containing propylene glycol, 
glycerol, water, flavoring and nicotine or marijuana to vaporize (Lerner, et al., 2016). Through 
this process, metal nanoparticles are also released and inhaled by consumers (Lerner, et al., 
2016). These nanoparticles, particularly copper nanoparticles, lead to increased mitochondrial 
stress, DNA damage and oxidative stress (Lerner, et al., 2016). Human lung fibroblasts were 
exposed to various heavy metals found in vaping pens in an Air-Liquid Interface System culture 
(Lerner, et al., 2016). Damage was noted as quickly as fifteen minutes after exposure to e-
cigarette aerosols containing heavy metal nanoparticles (Lerner, et al., 2016). This finding 
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validates the notion that vaping is not a safer alternative to combustible cigarettes (Lerner, et al., 
2016). Cigarette smoke induces cell death via mitochondria dysfunction leading to apoptosis 
(Lerner, et al., 2016). E-cigarette aerosols also cause cellular and DNA damage through copper 
nanoparticle induced oxidative stress (Lerner, et al., 2016). These findings also show that there is 
a risk to vapers regardless of the type of e-cigarette solution consumed.  
 A final causative agent that underwent investigation was vitamin E acetate. Vitamin E is 
used commonly in multivitamins and lotions with minimal complications. Like other substances, 
there is limited to no data on the impact inhaling vitamin E acetate has on lung tissue (Blount, et 
al., 2020). Vitamin E acetate is used with THC-containing products to improve aroma and taste 
as well as lower the cost (Blount, et al., 2020). When EVALI cases were skyrocketing, vaping 
products were analyzed and nearly 50% of individuals with EVALI had detectable levels of 
vitamin E acetate in their vaping liquid (Blount, et al., 2020). Without any research to understand 
the cause of vitamin E acetate on lungs, researchers attempted to identify this substance as the 
causative agent of EVALI (Blount, et al., 2020).  
 Researchers obtained bronchoalveolar lavage (BAL) samples from bronchoscopies of 51 
patients with presumed EVALI (Blount, et al., 2020). These samples were compared to BAL 
samples from 99 healthy individuals. Samples were analyzed using isotope dilution mass 
spectrometry to identify possible toxicants (Blount, et al., 2020). In addition to vitamin E acetate, 
researchers were looking for DPPC, cannabinoids, plant oils and diluent terpenes, all 
hypothesized causative agents (Blount, et al., 2020). In the 51 EVALI cases, 48 had detectable 
levels of vitamin E acetate and no traces of other causes (Blount, et al., 2020). When compared 
to the healthy individuals, no level of vitamin E acetate was present (Blount, et al., 2020).  
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 While this information was promising in identifying the culprit, researchers did not yet 
know the mechanism of action for EVALI induced from vitamin E acetate (Blount, et al., 2020). 
Vitamin E acetate, also known as alpha-tocopheryl acetate, has a long aliphatic tail (Blount, et 
al., 2020). This tail would allow the molecules to penetrate surfactant leading to changes in 
surfactant consistency from gel to crystalline (Blount, et al., 2020). When this occurs, surfactant 
is unable to maintain the surface tension necessary to keep the small airways open (Blount, et al., 
2020). Even worse, vitamin E acetate can dissociate at high temperatures with a biproduct of 
ketene, a known respiratory irritant (Blount, et al., 2020). Both of these factors place Vitamin E 
Acetate as the likely culprit of EVALI, not nicotine or THC (Blount, et al., 2020).   
 As mentioned earlier, EVALI was due to exogenous lipoid pneumonia. Though vitamin E 
acetate, found in THC-containing e-cigarette liquid, is a key player, it is not the only factor that 
makes e-cigarettes dangerous (Blount, et al., 2020). Propylene glycol and glycerol can cause 
dehydration and irritation of fragile alveoli leading to a change in surface tension and surfactant 
functionality (Chaumont, et al., 2019). Copper nanoparticles elicit DNA damage and oxidative 
stress leading to inflammation and possible long-term changes to lung cell function and structure 
(Lerner, et al., 2016).  
Gaps in the Literature 
 As mentioned throughout this paper, there are numerous serious gaps in literature. Initial 
review of the literature revealed few high level research evidence. The majority of current data 
available being expert opinion or case studies. Electronic cigarettes have been on the market for 
almost fifteen years, unfortunately there is limited longitudinal studies to guide providers though. 
Research into the longitudinal effects of vaping needs to be conducted. There is also a need for 
high quality randomized control trials to prove the severity of adverse effects. Direct RCTs may 
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be difficult and unlikely due to ethical issues involving adolescents and young adult health, but 
cohort studies are an alternative. Additionally, research is needed to ascertain how chemicals 
affect the body when inhaled versus ingested. 
Discussion 
 During the late summer of 2019, an influx of respiratory symptoms in young vapers is 
partially attributed to the addition of Vitamin E Acetate to THC containing vaping liquids. 
Vitamin E Acetate improved taste and decreased cost for dealers but induced exogenous lipoid 
pneumonia in consumers. Vitamin E Acetate penetrates surfactant, changing the surface tension 
in the lungs leading to lung dysfunction (Blount, et al., 2020). Removing Vitamin E Acetate 
from vaping liquid is prudent to preventing more EVALI cases. Alas there is limited regulation 
in regard to manufacturing marijuana-containing vaping liquids due to limited legalization 
(Poklis, et al., 2019). Adolescents who vape marijuana are at an increased risk for EVALI 
compared to adolescents who do not vape marijuana. 
 The aforementioned statements should not be interpreted as deeming vaping nicotine or 
other products as safe. Other factors that promote lung dysfunction with vaping are the 
humectants propylene glycol and glycerol. Both components are deemed “safe” for consumption, 
but this does not translate to mean safe for inhaling the substances. When inhaled, these 
hygroscopic compounds dehydrate surrounding structures by absorbing adjacent fluid. This 
change in moisture level effects mucocilliary clearing in the bronchioles causing inflammation 
and obstruction (Chaumont, et al., 2019).  
 Combustible cigarette smoke has thousands of carcinogenic products, but electronic 
cigarette aerosol is not without risk. Consumers are also at risk for adverse effects from vaping 
due to the metal heating coil. The coil can release heavy metal nanoparticles that are inhaled into 
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the lungs. These nanoparticles, particularly copper, induce mitochondrial stress, damage cellular 
DNA and lead to oxidative stress (Lerner, et al., 2016).  
 In regard to marijuana consumption, it was thought to be inevitable that marijuana and 
electronic cigarettes would combine. Unfortunately, even though this has happened, there is a 
significant lack in regulation surrounding marijuana manufacturing. Products like CBD that have 
been promoted as healthy contain significant impurities. 5F-ADB and dextromorphone lead to 
serious complications including psychosis or death (Poklis, et al., 2018). Identification of these 
cannabimimetics is concerning since they are not naturally occurring in marijuana. The lack of 
regulation surrounding marijuana products must be addressed to protect consumers.  
 As providers, the goal is to do no harm and educate patients on decisions that will 
provide them with the highest quality of health. It is difficult for providers to accomplish this 
goal in regard to electronic cigarettes due to the lack of research, and lack of regulation. When a 
patient presents attempting to quit combustible smoking, electronic cigarettes have been deemed 
as effective as other FDA approved smoking cessation tools. But electronic cigarettes have 
significant risks and too many unknowns to make them a safe alternative to combustible 
cigarettes. Also, with the identification of vitamin E acetate, propylene glycol and glycerol as 
potentially harmful agents, providers can suggest patients understand what is in the liquid they 
are vaping. Reading labels and educating patients on risk factors will be beneficial for patients to 
protect themselves.  
Implications for Future 
Recommendations for Clinical Practice  
The initial presenting feature for 95% of patients with EVALI was vague respiratory 
symptoms (Blount et al, 2020). A thorough history in a nonjudgmental way is imperative to 
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illicit behavioral choices surrounding vaping and substance use. Understanding what substances 
are vaped, where these substances were obtained, frequency of vaping and duration of vaping are 
key questions. If EVALI is suspected, initial diagnostics include chest radiograph, CBC, liver 
transaminases, ESR and urine toxicology. Chest radiograph may show signs of lipoid pneumonia 
including bibasilar, ground glass opacities and tree-in-bud findings. If patient has history of 
respiratory illness that will decrease pulmonary reserve, such as asthma, oxygen saturation <95% 
on room air or signs of respiratory distress, admission to hospital with pulmonary consultation is 
warranted. If treated outpatient, empirical medications include corticosteroids, antibiotics for 
community acquired pneumonia (Amoxicillin plus a macrolide) and antivirals as appropriate. 
Patient should be followed-up in clinic within 24-48 hours and demonstrate proper education on 
worsening symptoms that would warrant admission (Ramirez, 2019; Siegel, 2019).  
Recommendations for Research 
EVALI is an evolving health problem and therefore has minimal high-level evidence. It is 
proposed that decreasing amount of inhaled toxic smoke from combustible cigarettes, which 
contains tar, ammonia, carbon monoxide and hydrogen cyanide will improve respiratory 
symptoms, but no research has taken place to support or dispute this hypothesis (Budney, et al., 
2015).  Other research has begun to understand the negative effects of humectants in the lungs. 
Research is needed to understand how other biproducts such as Vitamin E, coconut oil, effect the 
body when inhaled. It is also necessary to perform longitudinal studies on individuals to assess 
systemic effects of electronic cigarette use over time.   
Recommendations for Education  
Providers and patients need to be educating on the associated risks with vaping and the 
lack of evidence to support vaping as a healthier alternative to smoking. Education is also needed 
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surrounding marijuana as this will become more and more common with increasing legalization. 
Adolescents in high-density dispensary areas are two times more likely to vape marijuana than 
their counterparts living in other areas (Knopf, 2018). Therefore, education should be prioritized 
for schools and families in these areas so they are informed of the risk of vaping and the risk of 
using marijuana at a young age (decreased brain development, lower educational achievement).  
 There is also education needed for providers in identifying EVALI. While cases have 
decreased, it is important to identify these cases early as patients can decompensate quickly if not 
treated appropriately. Providers should ask all patients a thorough social history regarding vaping 
and educate tobacco users that vaping is not a good option for smoking cessation (Truth 
Initiative, 2019). Any individual who vapes should be encouraged to quit, especially those 
vaping marijuana (Moritz, et al., 2019). Additionally, symptomatic patients should obtain a chest 
radiograph which may show bibasilar infiltrates. EVALI is a diagnosis of exclusion so empirical 
treatment of possible community acquired pneumonia is indicated. If admitted, high dose 
methylprednisone was shown to decrease airway inflammation and improve respiratory 
symptoms (Dicpinigaitis, et al., 2019).  
Recommendations for Policy  
There is a need for more regulation surrounding cannabis production. Currently, people 
are using cannabis concentrates that are higher in potency than marketed due to lack of 
regulation (Budney, et al., 2015). Without regulation, there is no means for consumers to know 
the ingredients of the product they are consuming leading to large variations in purity and 
potency. This variability is quite dangerous as increased consumption of highly potent 
cannabinoids have been linked to psychotic episodes. Therefore, as legalization of marijuana 
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continues to grow, it is imperative that there are policies in place to regulate the potency and 
purity of cannabinoid concentrates (Budney, et al., 2015).  
Another policy consideration is the density of dispensaries. Adolescents that live in an 
area with high numbers of dispensaries in a small area (therefore high density) have a two-time 
higher likelihood of vaping marijuana and are more likely to start at a younger age. This is 
concerning since chronic cannabis use in adolescence is associated with inhibited brain 
development leading to lower educational achievement and psychosocial functioning (Knopf, 
2018). There is also a positive association between length of legalization and likelihood of 
vaping in that the longer a state has legalized marijuana, the adolescent is more likely to have 
vaped (Knopf, 2018). This is important information for legislators to remember as legalizing 
recreational marijuana is gaining traction. Limiting the number of dispensaries or not allowing 
dispensaries within certain areas of schools may help deter adolescents from trying marijuana.  
Additionally, regulation regarding electronic cigarette usage in smoke-free zones is 
needed. Years of work and legalization may be undermined with electronic cigarettes being used 
in schools and other public places. Due to their discrete design, it is difficult to identify vape 
pens. Also, there is no research on any second-hand effects of those inhaling the vapor or 
flavorings inadvertently.  
Conclusion 
 The spike in EVALI from August 2019 to December 2019 can be partially attributed to 
Vitamin E Acetate. This substance has the same consistency of THC oil, so it is used to cut THC 
oil and increase profits for distributors. Vitamin E Acetate is not used in e cigarettes containing 
nicotine (Blount, et al., 2020). Therefore, those individuals who used THC containing e-
cigarettes were at an increased risk for EVALI compared to those who did not consume THC. 
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This does not mean that there are no side effects associated with vaping nicotine or other 
marijuana products. Vaping products that contain propylene glycol and glycerol are at risk for 
increased lung injury and inflammation due to changes in surfactant and gas exchange 
(Chaumont, et al, 2019). 
 Due to lack of regulation surrounding marijuana containing vape solution, consumers are 
at an increased risk for complications. Without regulation, purity and potency levels are not 
guaranteed. Additionally, as recreational marijuana becomes legalized in more states, 
adolescents are at an increased chance of vaping at a younger age if they live in an area with high 
dispensary density (Knopf, 2018). Providers need to stay abreast on these topics to ensure they 
are educating patients appropriately and identifying any complications associated with vaping. 
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Appendix  
Table 1 
 
Database Search Description 
Database Restrictions Added 
to Search 
Dates Included in 
Database 
General Subjects 
Covered by 
Database 
CINAHL Plus Full Text, peer 
reviewed 
2015-2019 Nursing e-books and 
journals covering all 
aspects of nursing 
and other medical 
professions 
MEDLINE (PubMed) Full text, peer 
reviewed 
2015-2019 Citations, abstracts 
and full text articles 
for health 
professionals in the 
health care system
  
Cochrane  Apply related words, 
search within text 
2015-2019 Bibliography of 
controlled trials 
Academic Search 
Premier 
Full Text, peer 
reviewed 
2015-2019 Over 4,600 
publications covering 
all areas of interest 
Nursing and allied 
Health Database 
Full Text, peer 
reviewed, Adolescent 
(13-18)  
2015-2019 All aspects of nursing 
and affiliated 
healthcare 
 
Table 2 
 
Data Extraction Process 
Date of 
Search 
Key Words CINAHL MEDLINE 
(PubMed) 
Cochrane Academic 
Search 
Premier 
Nursing 
and allied 
Health 
Database 
10/10/19 Vaping 
Cannabis 
35(9) 81  2(1) 87 (10) 69 (7) 
10/10/19 ‘Vaping 
cannabis’ AND 
‘lung injury’ 
2(2) 7(3) 0 4 (2) 16 (2) 
10/10/19 ‘Vaping 
cannabis’ AND 
‘lung injury’ 
AND 
‘adolescents 
0 1 (1) 0 11 (1) 9 (1) 
10/22/19 ‘Vaping or e-
cigarettes’ AND 
569 5 (5) 77 (4) 317 317 
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Date of 
Search 
Key Words CINAHL MEDLINE 
(PubMed) 
Cochrane Academic 
Search 
Premier 
Nursing 
and allied 
Health 
Database 
lung injury’ 
AND 
‘adolescent’ 
10/25/19 ‘vaping’ AND 
‘lung disease’ 
11 35 (5) 5 (2) 34 (4) 109 
10/25/19 ‘vaping’ AND 
‘teens’ AND 
‘lung disease’ 
1 (1) 15 (3) 0 3 (0) 18 (3) 
 
 
 
11/12/19 ‘cannabidiol’ 
AND ‘e-
cigarette 
3 (2) 6 (0) 0 6(1) 15 (3) 
BOLD: articles reviewed for match with systematic review inclusion criteria. 
• Some of the bold articles are seen in multiple databases leading to skewed numbers 
• Searches yielding more than 100 results were refined prior to evaluating articles 
 
Table 3 
 
Characteristics of Articles Included and Excluded 
Reference Included or Excluded Rationale 
Ahmad, S.., Zafar, I., 
Mariappan, N., 
Husain, M., Wei, C.-
C., Vetal, N., . . . 
Ahmad, A. (2019). 
Acute pulmonary 
effects of aerosolized 
nicotine. American 
Journal of physiology, 
L94-L104. 
 
Excluded Focus on nicotine 
 
MULTIPLE DATABASES 
Atkins, G. (2015). Acute 
inhalational lung 
injury related to the 
use of electronic 
nicotine delivery 
system. Chest 
Infections, 83A. 
 
Excluded Focus on nicotine 
Blount, B. C., Karwowski, M. 
P., Shields, P. G., 
Morel-Espinosa, M., 
Included Vitamin E Acetate link to 
EVALI 
 28 
Reference Included or Excluded Rationale 
Valentin-Blasini, L., 
Gardner, M., . . . 
Cowan, E. (2020). 
Vitamin E acetate in 
bronchoalveolar-
lavage fluid 
associated with 
EVALI. The New 
England Journal of 
Medicine, 697-705. 
 
Budney, A. J., Sargent, J. D., 
& Lee, D. C. (2015). 
Vaping cannabis 
(marijuana): parallel 
concerns to e-cigs? 
Society for the study 
of addiction, 1699-
1704. 
 
Included Impact of vaping cannabis 
 
MULTIPLE DATABASES 
Chaumont, M., van de Borne, 
P., Bernard, A., Van 
Muylem, A., Deprez, 
G., Ullmo, J., . . . 
Debbas, N. (2019). 
Fourth generation e-
cigarette vaping 
induces transient lung 
inflammation and gas 
exchange 
disturbances: Results 
from two randomized 
clinical trials. 
American Journal of 
Physiology, L705-
L719. 
 
Included Vaping, regardless of 
marijuana, leads to impaired 
arterial oxygen tension 
 
MULTIPLE DATABASES 
Davidson, K., Brancato, A., 
Heetderks, P., 
Mansour, W., 
Matheis, E., Nario, 
M., . . . Fox, D. 
(2019). Outbreak of 
electronic-cigarette-
associated acute lipoid 
Included Pathophysiology behind 
EVALI 
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Reference Included or Excluded Rationale 
pneumonia-North 
Carolina, July-August 
2019. Morbidity and 
Mortality Weekly 
Report. 
 
Davies, M. J., Birkett, J. W., 
Kotwa, M., 
Tomlinson, L., & 
Woldetinsae, R. 
(2017). The impact of 
cigarette/e-cigarette 
vapour on simulated 
pulmonary surfactant 
monolayers under 
physiologically 
relevant conditions. 
Surface and interface 
analysis, 654-665. 
 
Excluded Cigarettes versus e-cigarettes 
Dicpinigaitis, P. V., Trachuk, 
P., Fakier, F., Teka, 
M., & Suhrland, M. J. 
(2019). Vaping-
associated acute 
respiratory failure due 
to acute lipoid 
pneumonia. Lung, 1-4. 
 
Included Increased evidence 
supporting link between 
cannabis vaping and lipoid 
pneumonia 
Ewing, S. W., Lovejoy, T. I., 
& Choo, E. K. (2017). 
How has legal 
recreational cannabis 
affected adolescents 
in your state? A 
window of 
opportunity. American 
Journal of Public 
Health, 246-247. 
 
Excluded Opinion piece, not focused on 
vaping marijuana but instead 
marijuana use in any form 
(edibles, etc.) 
He, T., Oks, M., Esposito, 
M., Steniberg, H., & 
Makaryus, M. (2017). 
'Tree-in-bloom': 
Severe acute lung 
Excluded Single case-study. Middle-
aged male.  
 
MULTIPLE DATABASES 
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Reference Included or Excluded Rationale 
injury induced by 
vaping cannabis oil. 
Annals of the 
American Thoracic 
Society, 468-470. 
 
Knopf, A. (2018). Teen 
cannabis vaping and 
edibles increased in 
cannabis states. 
Alcoholism & drug 
abuse weekly, 5-7. 
 
Included Legalizing marijuana and 
increased number of 
dispensaries increases vaping 
use 
 
MULTIPLE DATABASES 
Lerner, C. A., Rutagarama, 
P., Ahmad, T., 
Sundar, I. K., Elder, 
A., & Rahman, I. 
(2016). Electronic 
cigarette aerosols and 
copper nanoparticles 
induce mitochondrial 
stress and promote 
DNA fragmentation in 
lung fibroblasts. 
Biochemical and 
biophysical research 
communities, 620-
625. 
 
Included Vaporized oxidants lead to 
mitochondrial stress 
Miech, R., Johnston, L., 
O'Malley, P. M., 
Bachman, J. G., & 
Patrick, M. E. (2019). 
Trends in adolescent 
vaping, 2017-2019. 
New England Journal 
of Medicine. 
 
Excluded Nicotine vaping rates only 
Moritz, E. D., Zapata, L. B., 
Kekiachvili, A., 
Glidden, E., Annor, F. 
B., Werner, A. K., . . . 
Pet. (2019). Update: 
Characteristics of 
patients in a national 
Included Midwest Outbreak, Patient 
characteristics 
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Reference Included or Excluded Rationale 
outbreak of e-
cigarette, or vaping, 
product use-associated 
lung injuries-United 
States, October 2019. 
MMWR: Morbidity & 
Mortality Weekly 
Report, 985-989. 
 
Palazzolo, D. L. (2013). 
Electronic cigarettes 
and vaping: A new 
challenge in clinical 
medicine and public 
health. A literature 
review. National 
Library of Medicine, 
1-20. 
 
Included Literature review from 2008-
2013 e-cigarette use 
Poklis, J. L., Mulder, H. A., 
& Peace, M. R. 
(2018). The 
unexpected 
identification of the 
cannabimimetic, 5F-
ADB, and 
dextromethorphan in 
commercially 
available cannabidiol 
e-liquids. Forensic 
Science International, 
e25-e27. 
 
Included Unregulated marijuana 
products can lead to increased 
risk 
Siegel, D. A., Jatloui, T. C., 
Koumans, E. H., 
Kiernan, E. A., Layer, 
M., Cates, J. E., . . . 
Mitchk. (2019). 
Update: Interim 
guidance for health 
care providers 
evaluating and caring 
for patients with 
suspected e-cigarette, 
or vaping, product use 
Included Midwest Outbreak, clinician 
guidelines 
 
MULTIPLE DATABASES 
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Reference Included or Excluded Rationale 
associated lung 
injury- United States, 
October 2019. 
MMWR: Morbidity 
and Mortality Weekly 
Report, 919-927. 
 
Viswam, D., Trotter, S., 
Burge, S. P., & 
Walters, G. I. (2018). 
Respiratory failure 
caused by lipoid 
pneumonia from 
vaping e-cigarettes. 
BMJ Case Reports, 1-
4. 
 
Included Case study that discusses 
glycol as culprit to lipoid 
PNA not marijuana/THC or 
nicotine 
Windle, S. B., Wade, K., 
Filion, K. B., 
Kimmelman, J., 
Thombs, B. D., & 
Eisenberg, M. J. 
(2019). Potential 
harms from 
legalization of 
recreational cannabis 
use in Canada. 
Canadian Journal of 
Public Health, 222-
226. 
 
Excluded Information specific to 
Canada (indigenous people, 
regulations etc.) 
Shaded rows indicate included articles 
 
Table 4 
 
Literature Review Table of All Studies Included 
Citation Study 
Purpose 
Pop(N)/
Sample 
Size (n) 
Study 
Design/Leve
l of 
Evidence 
Variables
/ 
Instrume
nts 
Interv
ention 
Findin
gs 
Implicati
ons 
Blount 
(2020) 
Diagnosti
c proof of 
Vitamin 
E linkage 
51 
patients 
with 
confirm
Level III: 
case-cohort 
study 
Assess 
BAL 
washings  
91 
health
y 
BAL 
Vitami
n E 
was 
the 
only 
Vitamin 
E as one 
of the 
causes of 
EVALI 
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Citation Study 
Purpose 
Pop(N)/
Sample 
Size (n) 
Study 
Design/Leve
l of 
Evidence 
Variables
/ 
Instrume
nts 
Interv
ention 
Findin
gs 
Implicati
ons 
to 
EVALI 
ed 
EVALI 
washi
ngs 
contam
inant 
present 
Budney, 
 Sargent &  
Lee (2015) 
 
Prompt 
awarenes
s for the 
need for 
increased 
scientific 
research 
into 
marijuana 
vaping 
 Level IV: 
Case Series 
Vaping 
cannabis 
or 
cannabino
ids, e-
cigarette 
use 
 Lack 
of 
quality 
researc
h 
regardi
ng 
vaping 
mariju
ana 
Need for 
increased 
scientific 
research 
on the 
long-term 
effects of 
cannabis 
vaping 
Chaumont 
et al (2019) 
Assess 
effects of 
e-
cigarettes 
on 
inflamma
tion, gas 
tension 
and PFTs 
25 
young 
tobacco 
users 
Level II Vaping  Vape 
with 
or 
witho
ut 
nicoti
ne 
Vaping 
induce
d 
airway 
epithel
ial 
injury 
Glycerol 
and 
propylen
e glycol, 
not 
nicotine 
or THC 
may be 
the cause 
of 
EVALI 
Davidson, 
et al (2019) 
Pathophy
siology 
of 
EVALI 
5 North 
Carolina 
Patients 
with 
history 
of 
vaping 
cannabis 
Level VII   Lipoid 
pneum
onia in 
all 5 
patient
s 
Possible 
pathophy
siology 
behind 
EVALI 
Dicpinigait
is (2019) 
Add 
informati
on to 
evolving 
understan
ding of 
EVALI 
28-year 
old male 
Level V   Acute 
lipoid 
pneum
onia 
due to 
vaping 
cannab
is 
Increased 
support 
for 
cannabis 
induced 
lung 
disease 
Knopf 
(2018) 
Assess 
the effect 
2,630 
cannabis
Level VI Facebook 
survey 
 Increas
ed 
As 
legalizati
 34 
Citation Study 
Purpose 
Pop(N)/
Sample 
Size (n) 
Study 
Design/Leve
l of 
Evidence 
Variables
/ 
Instrume
nts 
Interv
ention 
Findin
gs 
Implicati
ons 
of 
marijuana 
legalizati
on on 
how it is 
consume
d 
-using 
youth 
age 14-
18 
length 
of 
legaliz
ation 
and 
increas
ed 
numbe
r of 
dispen
saries 
correla
tes 
with 
increas
ed 
vaping 
of 
THC 
on of 
marijuan
a 
continues
, vaping 
THC 
products 
will 
become 
an 
increasin
g burden 
Lerner et 
al. (2016) 
Determin
e 
mechanis
m of lung 
injury 
from 
vaping 
 Level III/ 
case control 
DNA 
fragmentat
ion assay, 
ELISA, 2-
tailed t-
test 
Expos
ure of 
e-
cigaret
te 
aeroso
ls to 
lung 
cells 
E-
cigaret
te 
aerosol
s cause 
inflam
matory 
change
s 
E-
cigarettes 
with 
nicotine 
may have 
deleterio
us long-
term 
effects 
Copper 
nanoparti
cles 
Moritz, et 
al (2019) 
Describe 
patient 
characteri
stics and 
vaped 
substance
s as well 
as 
EVALI-
associate
d deaths 
1,604 
cases of 
EVALI 
with 34 
deaths 
Level VII: 
expert 
opinion 
Review of 
EVALI 
cases 
reported 
to CDC 
n/a 86% of 
patient 
with 
EVAL
I used 
THC-
contain
ing 
produc
ts 
within 
Encourag
e patients 
to avoid 
vaping 
THC-
containin
g 
products 
 35 
Citation Study 
Purpose 
Pop(N)/
Sample 
Size (n) 
Study 
Design/Leve
l of 
Evidence 
Variables
/ 
Instrume
nts 
Interv
ention 
Findin
gs 
Implicati
ons 
the 
previo
us 3 
months 
Palazzolo, 
 (2013) 
Literature 
Review 
73 
research 
articles 
Level V/ 
Literature 
Review 
  Need 
for 
more 
RCT 
and 
scientif
ic 
researc
h to 
guide 
practic
e 
More 
research 
is 
needed, 
unclear 
guideline
s for 
providers 
(benefit 
versus 
harm) 
Poklis, 
Mul
der 
& 
Pea
ce 
(20
18) 
Cannabid
iols 
contain 
surprising 
contamin
ants 
9 CBD 
infused 
liquids 
Level IV Analyze 
liquids via 
DART/M
S and 
GC/MS 
 5F-
ADB 
and 
dextro
methor
phan 
found 
in 
cannab
idiol 
produc
ts 
Unregula
ted 
distributi
on of 
these 
products 
increases 
consumer
s risk of 
injury 
Siegel, et 
al  
(2019) 
Provide 
practice 
guideline
s for 
practition
ers 
regarding 
EVALI 
339 
EVALI 
medical 
records 
submitte
d to 
CDC 
Level VII: 
expert 
opinion 
Review of 
EVALI 
cases 
reported 
to CDC 
n/a Pertine
nt 
history
, vitals, 
respira
tory 
viral 
panel, 
CBC, 
toxicol
ogy, 
CXR 
and 
Interim 
guidance 
for 
practition
ers 
 36 
Citation Study 
Purpose 
Pop(N)/
Sample 
Size (n) 
Study 
Design/Leve
l of 
Evidence 
Variables
/ 
Instrume
nts 
Interv
ention 
Findin
gs 
Implicati
ons 
CT 
chest 
Viswam et 
al (2018) 
Evaluate 
lipoid 
pneumoni
a 
associate
d with e-
cigarettes 
1 case 
report 
Level VII   Glycol 
leads 
to 
lipoid 
pneum
onia 
not 
other 
additiv
es 
No 
differenc
e in risk 
between 
THC and 
nicotine 
EVALI: electronic-cigarette (e-cigarette), or vaping, product use-associated lung injury 
RB-ILD: respiratory bronchiolitis interstitial lung disease 
DART/MS: Direct Analysis in real time mass spectrometry 
GC/MS: Gas chromatography mass spectrometry 
